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Poster Session II S333between the groups except a higher percentage of normal cytogenet-
ics in patients with FLT3/ITD+ (p 5 0.025).Two year OS, DFS,
non-relapse mortality (NRM), and relapse of cohort were 60.8%,
55.8%, 18.0% and 31.3%, respectively. Univariate analysis showed
FLT3/ITD+ compared to FLT3/ITD- patients was significantly as-
sociated with inferior DFS (2 year DFS: 19% vs. 64%, p\0.0027),
increased risk of relapse (1 year: 59%vs. 19%, p\0.0009), and a trend
towards decreased OS (p 5 0.08). 5 of the 16 FLT3/ITD+ patients
were also positive for NPM1, which did not impact outcome. Mul-
tivariate analysis using the Cox proportion hazard regression model
confirmed that FLT3/ITD+ mutations independently predicted
a shorter DFS (hazard ratio [HR], 3.0; 95% CI, 1.4-6.5; p 5
0.004) and increased risk of relapse (HR, 4.9; 95% CI, 2.0-12.3,
p 5 0.001). Time to relapse in patients with FLT3/ITD+ was very
short with 100 days cumulative risk of 45%.
Conclusion:Our data suggests that allo-SCT in FLT3/ITD+ AML
CR1 does not appear to overcome the poor prognostic value, and
these patients remain at high risk of early relapse even after allo-
SCT.While our study is limited by small size, this further illustrates
the urgent need for larger prospective studies to validate the efficacy
of allo-SCT in CR1 and the need to design therapy targeting FLT3/
ITD either prior to or early-post transplant to decrease relapse for
this specific subgroup.347
THIOTEPA (Tt), BUSULFAN (Bu), AND CLOFARABINE (Clo) AS A CONDI-
TIONING THERAPY FOR ALLOGENEIC HEMATOPOETIC STEM CELL
TRANSPLANT FOR PATIENTS WITH HIGH RISK MALIGNANCIES: UP-
DATED RESPONSE AND ENGRAFTMENT DATA
Worth, L.L.1, Andersson, B.S.2, Kelly, S.S.1, Petropoulos, D.1, Lee, D.A.1,
Kebriaei, P.2, Cooper, L.J.N.1, Champlin, R.E.2 1M D Anderson Cancer
Center, Houston, TX; 2M D Anderson Cancer Center, Houston, TX
Introduction: Fludarabine (F) and Busulfan (Bu) is a well-tolerated
conditioning regimen for allo HSCT. New nucleoside antimetabo-
lites are available with the potential for improved anti-tumor effect.
We substituted Clofarabine (Clo) for F for its better antileukemic ac-
tivity. To address the blood-brain barrier we added Thiotepa (Th),
a polyfunctional alkylating agent. These data report on combining
the Th + (IV)Bu + Clo in a conditioning regimen for high risk pa-
tients.
Patients and Methods: 31 patients received Th 5 mg/kg over 1 hr.
Bu was administered x 3 days over 3 hr to a daily AUC of 5,000
mcMol-min +/-10%. Clo 40mg/m2 was infused over 1 hr daily x 4
days. 29 patients are evaluable for engraftment and survival beyond
day + 30. M/F: 18/13. Median age 18 y (range 2-60). 16 patients
had AML [IF (2), relapse refractory (4), relapse untx(3), CR2 (6),
. CR2 (1)]. 14 patients had ALL [CR1 (1), CR2 (4), CR3 (5), Re-
lapse sensitive (2), relapse resistant (1) relapse untx(1)]. One patient
had CML ($ 3 CP). 7 had received prior transplants this being their
2nd (4), 3rd (2), 4th (1)]. GVHDprophylaxis was tacrolimus andmini-
MTX or tacrolimus and MMF (CB recipients). Those with one
Ag-mism or unrelated grafts received rabbit-ATG. Stem cell sources
included cord (17); MUD-apheresis (4), MUD-BM (5), MSD–
apheresis (4) MSD-BM (1).
Results: 15 patients are alive although 3 have relapsed (d132, d139,
d231) for a median OS 320 d (120-833). Common regimen-related
toxicities were GI and esophagitis. Self-limited hemorrhagic cystitis
due to BK virus occurred in 7 patients. Deaths from VOD/Pulmo-
nary hemorrhage (4) occurred in patients receiving Gemtuzumab
Ozogamicin or Inotuzumab ozogamicin therapy. Acute GVHD oc-
curred in  50% of all patients Grade II-IV (7). None (12) NE (4).
Chronic GVHD occurred in 5 patients, none (19), NE (7). Deaths
(16) were due to relapse (9) PFS 90 d (30-279), late infection (1)
d 259. The other 6 patients who died all received ozogamicin ther-
apy. PB microsatellite chimerism at day +30 showed 100% donor
T cell and myeloid cells in all but 4 patients who went on to relapse.
Conclusion: This regimen is overall safe unless administered after
recent ozogamicin therapy. Significantly, patients with refractory
disease at the time of HSCT achieved a CR. Engraftment in recipi-
ents of UCB transplants was robust (medium 18 days). In aggregate,
this chemotherapy regimen provided an anti-leukemia effect and
warrants further investigation.348
ADOPTIVE IMMUNOTHERAPY USING ANTI-THYMOCYTE GLOBULIN AND
REDUCED INTENSITY TOTAL BODY IRRADIATION; A COST-EFFECTIVE
STRATEGY FOR ALLOGENEIC STEM CELL TRANSPLANTATION
Shickle, L.M.2, Hazlett, A.F.1, Jin, Y.2, Sabo, R.T.1, Korshin, T.2,
Chung, H.M.1, McCarty, J.M.1, Clark, W.B.1, Toor, A.A.1,
Roberts, C.H.1 1VCU Massey Cancer Center, Richmond, VA; 2VCU
Massey Cancer Center, Richmond, VA
Allogeneic stem cell transplants (SCT) conditioned with conven-
tional regimens continue to be fraughtwith complications, increasing
resource utilization and downstream costs associated with these
procedures. We have developed an investigational conditioning reg-
imen, incorporating anti-thymocyte globulin (ATG; Thymoglobu-
lin, Sanofi-Aventis) and reduced-intensity total body irradiation,
with the goal of reducing complications following SCT
(NCT00709592). To determine the cost savings associated with
the use of this regimen, we performed a retrospective analysis of di-
rect costs incurred during the first 100 days following SCT.We com-
pared the investigational group of patients (IG; n5 25) with a control
group transplantedduring the same timeperiodand conditionedwith
either reduced intensity busulfan ormelphalan + fludarabine contain-
ing regimens (CG; n5 32). The IG and CG differed in age (57 vs. 53
years; F-Test, p5 0.04), number of prior regimens (4 vs. 2; p\0.01),
and disease distribution (p\0.001), but had a similar proportion of
matched related and unrelated donors (p 5 0.12). At a median fol-
low-up of 20months in the IG and 12months in the CG, the survival
in the two groups is similar (one-year K-M survival estimate 73% vs.
53%, Log Rank p 5 0.16). Inpatient hospitalization following SCT
was shorter for IG, 17 (67) days, compared to the CG, 24 (616)
days (p 5 0.02). Direct cost incurred during the study period was
lower for the IG ($121,103 6 47,292) compared to the CG
($194,392 6 93,760) (p\0.01), this despite the entire IG surviving
to day 100 (4 deaths in the CG). When patients who relapsed or
died during this period were excluded from analysis the cost differ-
ence remained in favor of the IG, $118,546 6 48,567 vs. $188,239
6 92,484 for the CG (p\0.01). Table 1 displays the trends in the
cost incurred over time for the investigational and control groups.
The cost savings spanned a variety of categories, including pharma-
ceutical, blood bank, laboratory and inpatient charges. We conclude
that despite being heavily pretreated, patients conditioned with the
investigational ATG + TBI regimen spent fewer days in the hospital
and had a lower cost associated with transplantation. Given the cur-
rent economic climate, our findings suggest that rethinking conven-
tional methods of reduced-intensity conditioning, with emphasis on
adoptive immunotherapy rather than dose intensity,may improve the
cost-effectiveness of allogeneic SCT.
Table 1. Total and InpatientCostsUpToDay100FollowingSCT
Time Period Control Group Investigational Group p ValueTotal Costs
1-100 Days $194,392 $121,103 <0.01
1-30 Days $70,750 $49,306 <0.01
31-60 Days $30,216 $16,028 <0.01
61-100 Days $37,841 $16,709 0.05
Inpatient Costs
1-100 Days $51,442 $36,084 0.04
1-30 Days $26,266 $21,411 0.06
31-60 Days $7,732 $1,706 0.02
61-100 Days $11,972 $2,008 0.04The costs are mean values and standardized to FY 2012 $. The p-value
was calculated using analysis of variance (F test).
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ENCOURAGING SURVIVAL FOR PATIENTS WHO HAD A SECOND UMBILI-
CAL CORD BLOOD TRANSPLANT FOR GRAFT FAILURE
Lund, T.C.1, Verneris, M.R.1, Tolar, J.1, Cao, Q.2, Weisdorf, D.J.2,
Wagner, J.E.2, Brunstein, C.G.2 1University of Minnesota, Minneapolis,
MN; 2University of Minnesota, Minneapolis, MN
After umbilical cord blood transplantation (UCBT), the 10-15%
risk of graft failure (GF) remains a significant source or morbidity
S334 Poster Session IIand mortality. In our institution, 734 patients received an UCBT
between 2000 and 2010. The focus of this study was 76 patients
(10.4%) who had primary (n 5 55) or secondary (n 5 21) GF. Pri-
mary GF was defined as failure to achieve an absolute neutrophil
count (ANC) $ 500/mcL for 3 consecutive by day +42 or chime-
rism \5% in all assessments after transplantation regardless of
ANC. Secondary GF was defined as loss of chimerism\5% after
having achieved 5% or more after UCBT, or ANC persistently be-
low 500/mcL after having achieved $ 500/mcL for 3 consecutive
days by day +42. Patients were grouped as those with malignant
disease/myeloablative conditioning (MA, n 5 28), malignant
disease/nonmyeloablative conditioning (NMA, n 5 26) and non-
malignant disease (non-Malig, n 5 22). The OS at 100 days for pa-
tients with primary GF was 49%(95%CI, 35-61%) and secondary
GF was 76%(95%CI, 52-89%) (p 5 0.03). Thirty-nine patients un-
derwent a second transplant at a median time of 50 days (range:
32-565). Excluding patients with slow primary engraftment (n 5
10), who were counted as primary GF, the remaining 27 patients
were considered too ill to withstand a second transplant. Second
transplant conditioning included: no additional conditioning (n 5
10), ATG/ALG 6 steroids (n 5 11), and chemotherapy 6
ATG/ALG (n 5 18). Cumulative incidence of engraftment after
2nd transplant was 77% at a median time of 16 days (range:
0-39). Engraftment was similar in all groups. After 2nd transplant,
OS was 69%(95%CI, 52-81%) at 100 days and 41%(95%CI,
26-56%) at 1 year. The day 100 survival was 32%(95%CI,
16-49%) for MA, 73%(95%CI, 52-86%) for NMA and
68%(95%CI, 45-83%) for non-Malig patients(p 5 0.01). In evalu-
ation of time to second transplant, the OS at 100 days was similar
for patients transplanted # 50 or . 50 days: (62%[95%CI,
38-79%] vs. 78% [95%CI, 51-91%] respectively, p 5 0.31); there
was also no difference in OS at 1 year (33%[95%CI, 15-53%] vs.
50%[95%CI, 26-70%] respectively, p 5 0.34). The most frequent
causes of death at day 100 after 2nd transplant were: second graft
failure, bacterial infection and disease recurrence. In conclusion,
patients with primary or secondary GF after UCBT who undergo
a second transplant have encouraging survival with over 40% sur-
viving 1 year, and identifying strategies to overcome graft failure
will help to improve upon this.Table 1. Demographic data of MDS patients underwent allo-
geneic HCT
N 5 79
Median Age at diagnosis, years (Range) 49.7 (19-65)
Median Age at transplant, years (Range) 51.0 (20-66)
Gender, M/F 43/36
IPSS#
High 17 (21.5%)
High Intermediate 40 (50.6%)
Low Intermediate 18 (22.8%)
Low 4 (5.1%)
Disease status at transplant
Complete remission 10 (12.7%)
Residual or active hematologic disease 69 (87.3%)
HCT-CI
0 22 (27.8%)
1-2 15 (20.0%)
$3 42 (52.2%)
HLA compatability
6/6 or 8/8 65 (72.3%)
4/6, 5/6 or 7/8 14 (27.7%)
Donor
Related 39 (49.4%)
Unrelated 40 (5.6%)
IPSS Cytogenetic classification
Favorable 26 (32.9%)
Intermediate 16 (20.2%)
Unfavorable* 37 (46.8%)
Monosomal karyotype 24 (30.4%)
#Internation Prognostic Scoring System.
*Unfavorable karyotypes include complex cytogenetic abnormality ($3
structural abnormalities) or abnormal chromosome 7.350
EXPRESSION OF a4b7 INTEGRIN ON PERIPHERAL BLOOD MEMORY
CD4+ T-CELLS AFTER ALLOGENEIC HCT CORRELATES WITH NON-
RELAPSE MORTALITY AND OVERALL SURVIVAL
Y.-B., Chen1, McDonough, S.2, Chen, H.3, Kennedy, J.1, Alyea, E.P.2,
Armand, P.2, Ballen, K.K.1, Cutler, C.2, Dey, B.R.1, Ho, V.T.2,
Koreth, J.2, McAfee, S.L.1, Spitzer, T.R.1, Antin, J.H.2, Soiffer, R.J.2,
Jagasia, M.3, Ritz, J.2 1Massachusetts General Hospital, Boston, MA;
2Dana-Farber Cancer Institute, Boston, MA; 3Vanderbilt University,
Nashville, TN
Background: Surface expression of a4b7 integrin, a gut-homing
lymphocyte trafficking molecule, on peripheral blood memory T-
cells has been shown to be increased in patients who develop acute
intestinal graft-vs.-host disease (GVHD) after allogeneic hemato-
poietic cell transplantation (HCT).Decreased expression of a4b7 in-
tegrin on regulatory T-cells at engraftment has also been shown to
correlate with the development of intestinal GVHD. We hypothe-
sized that a4b7 integrin expressingmemory T-cells in the peripheral
blood at day +15 and day +30 after HCT would be associated with
the development of acute intestinal GVHD and survival outcomes.
Methods: Serial samples at day +15 and day +30 from 84 patients un-
dergoing either RIC or myeloablative conditioning allogeneic HCT
with peripheral blood stem cells were analyzed. Median follow-up
was 661 days (range 39, 907 days) among survivors. T-cell subsets
chosen for analysis included na€ıve and memory (defined by expres-
sion of CD45RA and CD45RO, respectively) CD4+ and CD8+ T-
cells. Expression of a4b7 integrin was assessed by flow cytometry.
Results: Increased percentage of memory CD4+ T-cells expressing
a4b7 integrin at day +15 correlated with increased non-relapse
mortality (NRM) (p 5 0.005) and decreased overall survival (OS)
(p 5 0.016). The cumulative incidence of NRM was 25% (21 /
84) (95% CI 16%, 34%) in this cohort. Expression on any na€ıve
T-cell subset, on memory CD8+ T-cells, or at day +30 was notshown to correlate with outcomes. Further analysis showed that
conditioning intensity, donor type, GVHD prophylaxis regimen,
use of in vivo T-cell depletion, and underlying disease had no sig-
nificant effect on the % of memory CD4+ T-cells expressing a4b7
integrin. Expression of a4b7 integrin on any T-cell subset did not
correlate with the development of acute intestinal GVHD, al-
though there were only 5 cases of grade II and 7 cases of grades
III-IV disease in this cohort.
Conclusion: Expression of a4b7 integrin on memory CD4+ T-cells
at day +15 after HCT predicts for NRM and OS. Analysis with
a larger number of samples is planned to confirm these results, but
continued study of a4b7 integrin as a biomarker or target of inter-
vention after HCT is warranted. This biomarker may be valuable
in identifying a high risk subset of patients who could benefit from
pre-emptive organ specific targeted intervention.
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OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT IN MYELODYS-
PLASTIC SYNDROMES WITH MONOSOMAL KARYOTYPE: AN ADVERSE
PROGNOSTIC FACTOR IN ADDITION TO CONVENTIONAL UNFAVORABLE
KARYOTYPE
Wudhikarn, K.1, Van Rheeden, R.2, Leopold, C.3, Rattanaumpawan, P.4,
Gingrich, R.D.1, Silverman, M.1 1University of Iowa Hospital and Clinic,
Iowa City, IA; 2University of Iowa Hospital and Clinic, Iowa City, IA;
3University of Iowa Hospital and Clinics, Iowa City, IA; 4University of
Pennsylvania School of Medicine, Philadelphia, PA
Introduction: Monosomal karyotype (MK) is defined as the pres-
ence of two or more distinct autosomal monosomies or a single
monosomy associated with a structural abnormality. It was first de-
scribed as an adverse prognosis for acute myeloblastic leukemia. Re-
cently, Patnaik et al demonstrated adverse prognostic effect ofMK in
myelodysplastic syndromes (MDS). However, the effect of MK on
the allotransplant in MDS is not yet well described.
Methods: MDS patients who underwent allotransplant at the Uni-
versity of Iowa from 1990 to 2009 were retrospectively reviewed. Cy-
togenetic and patient’s data were abstracted from medical genetics
and transplant database. Patients were classified according to
